Handling seizure data: special problems.
Pierce
M W
MW
Parke-Davis Research Division, Warner-Lambert Company, Ann Arbor, MI.
Shu
V S
VS
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects*; D004827:Epilepsy / Q000188:drug therapy* / Q000209:etiology; D017029:Epilepsy, Complex Partial / Q000188:drug therapy / Q000209:etiology; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009557:Nipecotic Acids / Q000009:adverse effects / Q000627:therapeutic use; D000078308:Tiagabine; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D000927:Anticonvulsants; D009557:Nipecotic Acids; C017985:progabide; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000078308:Tiagabine